The allogeneic response and tumor immunity.
The strong allogeneic response to donor MHC molecules in transplantation and the weak response to tumor antigens represent two important and divergent but potentially interactive immune responses. A patient's response to allogeneic MHC molecules might promote an effective T-cell response to self MHC-restricted tumor peptides and the possibilities for this are discussed here. These allogeneic responses might successfully be harnessed to promote the immune eradication of metastatic cancer.
Fabre
J W
JW
Department of Clinical Sciences, Institute of Liver Studies Guy's, King's and St Thomas' School of Medicine, London, UK. john.fabre@kcl.ac.uk
D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007519:Isoantigens / Q000276:immunology*; D008285:Major Histocompatibility Complex / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000503:physiopathology; D010455:Peptides / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000502:physiology; D014184:Transplantation, Homologous
D006680:HLA Antigens; D007519:Isoantigens; D010455:Peptides